Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy

Inflammation and pain are two prevalent findings after ocular surgery. Corticosteroids are widely administrated as a core treatment to control post-surgical inflammation and pain. Improper patient adherence to post-operative eye drop regimens, limited bioavailability of topical eye drops, and the ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Brooks, Cassandra C, Jabbehdari, Sayena, Gupta, Preeya K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968807/
https://www.ncbi.nlm.nih.gov/pubmed/32021072
http://dx.doi.org/10.2147/OPTH.S238756
_version_ 1783489205409677312
author Brooks, Cassandra C
Jabbehdari, Sayena
Gupta, Preeya K
author_facet Brooks, Cassandra C
Jabbehdari, Sayena
Gupta, Preeya K
author_sort Brooks, Cassandra C
collection PubMed
description Inflammation and pain are two prevalent findings after ocular surgery. Corticosteroids are widely administrated as a core treatment to control post-surgical inflammation and pain. Improper patient adherence to post-operative eye drop regimens, limited bioavailability of topical eye drops, and the negative impact of preservatives used in many of these eye drops, has made a strong case for novel therapies in the treatment of post-operative pain and inflammation. This review of the literature will focus on the role of intracanalicular sustained-release dexamethasone (Dextenza, Ocular Therapeutix, Bedford, MA, USA) for the management of ocular inflammation and pain.
format Online
Article
Text
id pubmed-6968807
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69688072020-02-04 Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy Brooks, Cassandra C Jabbehdari, Sayena Gupta, Preeya K Clin Ophthalmol Review Inflammation and pain are two prevalent findings after ocular surgery. Corticosteroids are widely administrated as a core treatment to control post-surgical inflammation and pain. Improper patient adherence to post-operative eye drop regimens, limited bioavailability of topical eye drops, and the negative impact of preservatives used in many of these eye drops, has made a strong case for novel therapies in the treatment of post-operative pain and inflammation. This review of the literature will focus on the role of intracanalicular sustained-release dexamethasone (Dextenza, Ocular Therapeutix, Bedford, MA, USA) for the management of ocular inflammation and pain. Dove 2020-01-13 /pmc/articles/PMC6968807/ /pubmed/32021072 http://dx.doi.org/10.2147/OPTH.S238756 Text en © 2020 Brooks et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Brooks, Cassandra C
Jabbehdari, Sayena
Gupta, Preeya K
Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy
title Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy
title_full Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy
title_fullStr Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy
title_full_unstemmed Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy
title_short Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy
title_sort dexamethasone 0.4mg sustained-release intracanalicular insert in the management of ocular inflammation and pain following ophthalmic surgery: design, development and place in therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968807/
https://www.ncbi.nlm.nih.gov/pubmed/32021072
http://dx.doi.org/10.2147/OPTH.S238756
work_keys_str_mv AT brookscassandrac dexamethasone04mgsustainedreleaseintracanalicularinsertinthemanagementofocularinflammationandpainfollowingophthalmicsurgerydesigndevelopmentandplaceintherapy
AT jabbehdarisayena dexamethasone04mgsustainedreleaseintracanalicularinsertinthemanagementofocularinflammationandpainfollowingophthalmicsurgerydesigndevelopmentandplaceintherapy
AT guptapreeyak dexamethasone04mgsustainedreleaseintracanalicularinsertinthemanagementofocularinflammationandpainfollowingophthalmicsurgerydesigndevelopmentandplaceintherapy

Ejemplares similares